Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17136584 | BONE REPAIR COMPOSITION AND KIT | December 2020 | July 2024 | Allow | 43 | 4 | 0 | Yes | No |
| 17253891 | Gel-In-Oil Emulsion and Transdermally Absorbed Agent | December 2020 | December 2022 | Abandon | 23 | 1 | 0 | No | No |
| 17111940 | MAGNESIUM PHOSPHATE HYDROGELS | December 2020 | November 2022 | Allow | 24 | 0 | 0 | No | No |
| 17111645 | COMPOSITIONS AND METHODS FOR MASKING THE TASTE OF DRUGS | December 2020 | November 2024 | Abandon | 47 | 4 | 1 | Yes | No |
| 17059958 | ETHER/ESTER COMPOSITE POLYURETHANE FOAM COSMETIC | November 2020 | January 2025 | Abandon | 49 | 5 | 0 | Yes | Yes |
| 17058756 | Anti-Obesity Agent, Anti-Dementia Agent, Deodorant, Anti-Aging Agent, Anti-Glycation Agent, Anti-Type I Allergy Agent, Hypotensive Agent, Flavor Improving Agent, Muscle Enhancing Agent, and Bone Metabolism Improving Agent | November 2020 | March 2024 | Allow | 39 | 4 | 0 | Yes | No |
| 17101614 | CHITOSAN-COATED PLATINUM FERRITE-SILICA SPINEL NANOCOMPOSITE | November 2020 | March 2023 | Allow | 28 | 2 | 0 | Yes | No |
| 17080975 | METHODS OF ATTRACTING MALE CONOPOMORPHA CRAMERELLA | October 2020 | October 2023 | Abandon | 36 | 2 | 0 | Yes | No |
| 17066752 | SURFACTANT-FREE, WATER-FREE FOAMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES | October 2020 | January 2023 | Abandon | 28 | 1 | 0 | No | No |
| 17045628 | METHOD OF MANUFACTURING SPRAY-DRIED POWDERS | October 2020 | February 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17045033 | EASY-TO-TAKE GRANULAR PREPARATION AND METHOD FOR PRODUCING SAME | October 2020 | June 2022 | Abandon | 20 | 1 | 0 | No | No |
| 17030023 | SOLUTION FOR PROLONGING OPEN TIME OF FERTILIZATION HOLE OF FISH EGGS AND METHOD FOR INTRODUCING EXOGENOUS GENE THROUGH FERTILIZATION HOLE | September 2020 | September 2022 | Abandon | 24 | 2 | 0 | No | No |
| 16982805 | PROGESTERONE INTRAVAGINAL DEVICES | September 2020 | December 2021 | Allow | 15 | 1 | 0 | No | No |
| 16978865 | COSMETIC AGENT COMPRISING INSOLUBLE SUBSTANCE AND METHOD FOR MANUFACTURING SAME | September 2020 | July 2023 | Allow | 35 | 2 | 1 | No | No |
| 17012831 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | September 2020 | January 2021 | Allow | 4 | 0 | 0 | No | No |
| 17012823 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | September 2020 | December 2020 | Allow | 3 | 0 | 0 | No | No |
| 16970708 | PATHOGENIC BACTERIA | August 2020 | August 2024 | Allow | 48 | 4 | 1 | No | No |
| 16970175 | COMPOSITIONS FOR COATING EDIBLE SUBSTRATES AND METHODS OF MAKING AND USING THE SAME | August 2020 | October 2023 | Abandon | 38 | 3 | 0 | No | No |
| 16992527 | Films and Compositions Comprising the Same | August 2020 | June 2024 | Abandon | 46 | 2 | 0 | No | Yes |
| 16943190 | ANTI-ADHERENT COMPOSITION | July 2020 | January 2024 | Abandon | 41 | 4 | 1 | No | No |
| 16940357 | COMPOSITIONS AND METHODS FOR HAIR AND SCALP TREATMENT | July 2020 | September 2023 | Abandon | 37 | 2 | 1 | No | No |
| 16964424 | APPARATUS AND METHOD OF USING IN SITU SOLIDIFYING COMPLEX COACERVATES FOR VASCULAR OCCLUSION | July 2020 | September 2023 | Allow | 38 | 0 | 0 | No | No |
| 16959681 | IMMEDIATE-RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING KETOPROFEN LYSINE SALT | July 2020 | January 2024 | Abandon | 43 | 3 | 0 | No | No |
| 16916677 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | June 2020 | September 2020 | Allow | 2 | 0 | 0 | No | No |
| 16771945 | Zirconium-Based Cluster as an Antiperspirant and Deodorant Active | June 2020 | October 2023 | Allow | 40 | 3 | 1 | Yes | No |
| 16896132 | pH-Modulated Formulations for Pulmonary Delivery | June 2020 | December 2021 | Abandon | 18 | 1 | 0 | No | No |
| 16761053 | NEW DELIVERY SYSTEM | May 2020 | August 2023 | Allow | 40 | 3 | 0 | No | No |
| 16835282 | EVA SEGMENTED INTRAVAGINAL RINGS CONTAINING PROGESTERONE | March 2020 | May 2024 | Abandon | 49 | 4 | 0 | No | No |
| 16832171 | SALICYLIC ACID GEL | March 2020 | November 2024 | Allow | 56 | 6 | 0 | Yes | No |
| 16825806 | ORAL DELIVERY OF ENZYMES BY NANOCAPSULES FOR TARGETED METABOLISM OF ALCOHOL OR TOXIC METABOLITES | March 2020 | November 2022 | Abandon | 32 | 1 | 0 | No | No |
| 16818876 | COMPOSITIONS AND RELATED METHODS FOR RECONSTITUTING THE IMMUNE SYTEM OF A SUBJECT | March 2020 | October 2021 | Allow | 19 | 1 | 0 | No | No |
| 16817689 | TOFACITINIB ORAL SUSTAINED RELEASE DOSAGE FORMS | March 2020 | May 2021 | Allow | 14 | 0 | 0 | No | No |
| 16799020 | COMPOSITION COMPRISING AN ORGANIC LIQUID DILUENT AND A SPECIFIC HYDROXYALKYL METHYLCELLULOSE | February 2020 | November 2021 | Allow | 21 | 1 | 0 | No | No |
| 16795900 | ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHODS FOR THE PRODUCTION THEREOF | February 2020 | April 2022 | Abandon | 26 | 2 | 0 | No | No |
| 16793179 | PROCESS FOR PREPARING AN ACID RESISTANT CELLULOSE CAPSULE | February 2020 | June 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16307314 | Method For Preparation of Quick Dissolving Thin Films Containing Bioactive Material With Enhanced Thermal Stability | February 2020 | June 2023 | Abandon | 55 | 2 | 1 | Yes | No |
| 16637912 | ANTITHROMBOTIC MEDICAL MATERIAL USING NICKEL TITANIUM ALLOY | February 2020 | December 2021 | Allow | 22 | 1 | 0 | Yes | No |
| 16778526 | MONOLITHIC INTRAVAGINAL RINGS COMPRISING PROGESTERONE AND METHODS OF MAKING AND USES THEREOF | January 2020 | March 2022 | Allow | 26 | 1 | 1 | No | No |
| 16778120 | GASTROINTESTINAL SITE-SPECIFIC ORAL VACCINATION FORMULATIONS ACTIVE ON THE ILEUM AND APPENDIX | January 2020 | November 2022 | Allow | 34 | 2 | 2 | Yes | No |
| 16630904 | COSMETIC COMPOSITION COMPRISING COLEUS FORSKOHLII AND CASSIA OCCIDENTALIS AND/OR CASSIA ALATA, AND COMPOSITIONS FOR USE IN TREATING VITILIGO | January 2020 | June 2022 | Abandon | 29 | 2 | 0 | No | No |
| 16736749 | COMPOSITION AND METHODS FOR GENERATING AND SUSTAINING MOLECULAR HYDROGEN (H2) IN AQUEOUS SYSTEMS | January 2020 | December 2021 | Allow | 23 | 3 | 0 | Yes | No |
| 16624244 | STABLE TOPICAL TETRACYCLINE COMPOSITIONS | December 2019 | May 2024 | Abandon | 53 | 0 | 1 | No | No |
| 16623185 | PROTEIN ADSORPTION PREVENTING AGENT, PROTEIN ADSORPTION PREVENTING FILM, AND MEDICAL TOOL USING SAME | December 2019 | September 2024 | Allow | 57 | 4 | 1 | Yes | No |
| 16712857 | SHEET, IMAGE PROCESSING APPARATUS, AND METHOD FOR PROCESSING IMAGE | December 2019 | July 2024 | Abandon | 55 | 4 | 1 | Yes | No |
| 16712260 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | December 2019 | January 2021 | Allow | 13 | 0 | 0 | No | No |
| 16705199 | HYDROGEN SULFIDE SUSTAINED RELEASING DRESSING AND MANUFACTURING METHOD THEREOF | December 2019 | September 2022 | Allow | 34 | 3 | 1 | Yes | No |
| 16614826 | COSMETIC OR DERMATOLOGICAL PREPARATION CONTAINING A FISH EGG EXTRACT | November 2019 | May 2025 | Abandon | 60 | 2 | 1 | No | Yes |
| 16612994 | COATING FOR MEDICAL DEVICES | November 2019 | April 2023 | Allow | 41 | 2 | 0 | No | No |
| 16609509 | COSMETIC AND/OR DERMATOLOGICAL COMPOSITION, AND USES THEREOF IN THE COSMETIC FIELD AND IN THE ADJUVANT TREATMENT OF DERMATOLOGICAL PATHOLOGIES | October 2019 | September 2022 | Abandon | 35 | 2 | 1 | No | No |
| 16599629 | COMPRESSED NICOTINE LOZENGE | October 2019 | May 2023 | Allow | 43 | 4 | 1 | Yes | No |
| 16583734 | Dry Powder Inhalation Drug Products Exhibiting Moisture Control Properties and Methods of Administering the Same | September 2019 | March 2022 | Abandon | 30 | 2 | 0 | No | No |
| 16575120 | DICLOFENAC TOPICAL FORMULATION | September 2019 | January 2022 | Abandon | 28 | 2 | 0 | No | No |
| 16572359 | SOLVENT MODIFICATIONS TO PREMOISTENED SUBSTRATES | September 2019 | November 2023 | Abandon | 50 | 4 | 1 | No | No |
| 16493459 | Nanocomposite Ionic-Covalent Entanglement Reinforcement Mechanism and Hydrogel | September 2019 | May 2022 | Allow | 32 | 2 | 1 | No | No |
| 16552312 | Oral Care Composition | August 2019 | April 2021 | Allow | 20 | 1 | 0 | No | No |
| 16544276 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT, AND HIGH VISCOSITY LIQUID CARRIER MATERIAL | August 2019 | April 2021 | Abandon | 20 | 1 | 0 | No | No |
| 16505597 | Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture | July 2019 | March 2021 | Abandon | 21 | 1 | 0 | No | No |
| 16460518 | ORGANIC HYDROPEROXIDE REDUCTION IN PERFUMERY RAW MATERIALS | July 2019 | February 2022 | Allow | 31 | 4 | 0 | No | No |
| 16470439 | PERSONAL CARE COMPOSITIONS WITH GLUTATHIONE PRECURSOR COMPRISING NICOTINAMIDE AND AMINO ACIDS | June 2019 | May 2024 | Abandon | 59 | 5 | 0 | Yes | Yes |
| 16436695 | EMULSION | June 2019 | June 2021 | Allow | 24 | 2 | 0 | Yes | No |
| 16467249 | ORAL MEDICAMENT COMPRISING AN OSMOTIC LAXATIVE INCORPORATED INTO A MATRIX BASED ON PLANT FATS WITH REDUCED DOSES OF MACROGOL | June 2019 | July 2022 | Allow | 37 | 3 | 1 | Yes | No |
| 16425542 | ADHESIVE MEDICAL PRODUCTS AND METHODS FOR TREATING GASTROINTESTINAL LESIONS | May 2019 | September 2024 | Abandon | 60 | 6 | 0 | No | Yes |
| 16402523 | CAPSULES WITH A HIGH ACTIVE INGREDIENT CONTENT | May 2019 | June 2022 | Allow | 37 | 3 | 0 | No | No |
| 16341729 | Deodorizing Composition Comprising Zinc Neodecanoate | April 2019 | April 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16338765 | HAIR REPAIR COMPOSITION | April 2019 | February 2022 | Abandon | 34 | 8 | 0 | No | No |
| 16337319 | COMPOSITION FOR HEPATIC ARTERIAL CHEMOEMBOLIZATION USING HUMAN SERUM ALBUMIN NANOPARTICLES CARRYING ANTICANCER AGENT, AND METHOD FOR PRODUCING SAME | March 2019 | January 2023 | Allow | 46 | 4 | 1 | No | No |
| 16360394 | METFORMIN-CONTAINING DENTAL MATERIALS | March 2019 | October 2022 | Abandon | 43 | 3 | 1 | No | No |
| 16329299 | FORMULATION FOR ATROPINE SULFATE RAPIDLY-DISINTEGRATING SUBLINGUAL TABLETS | February 2019 | February 2025 | Allow | 60 | 7 | 1 | Yes | No |
| 16287509 | VITAMIN DELIVERY PARTICLE | February 2019 | April 2022 | Allow | 38 | 4 | 1 | Yes | Yes |
| 16327782 | COMPOUND, PRODUCTION METHOD THEREFOR, AND HYDROGEN SUPPLY METHOD | February 2019 | March 2023 | Allow | 48 | 5 | 1 | Yes | No |
| 16327794 | HYDROGEN SUPPLY MATERIAL AND PRODUCTION THEREFOR, AND HYDROGEN SUPPLY METHOD | February 2019 | October 2022 | Allow | 43 | 5 | 1 | Yes | No |
| 16282589 | METHOD OF SYNTHESIZING ANTIMICROBIAL SILVER NANOPARTICLES USING PIGEON DUNG | February 2019 | August 2021 | Allow | 30 | 4 | 0 | Yes | Yes |
| 16321618 | ANTI-INFLUENZA VIRUS COMPOSITION FOR MUCOUS MEMBRANES | January 2019 | March 2022 | Abandon | 37 | 0 | 1 | No | No |
| 16318034 | A PHARMACEUTICAL FORMULATION FOR ORAL ADMINISTRATION WITH IMPROVED CONTENT UNIFORMITY COMPRISING SUSTAINED-RELEASE PELLETS CONTAINING TAMSULOSIN HYDROCHLORIDE | January 2019 | December 2022 | Abandon | 47 | 2 | 0 | No | No |
| 16313739 | Transdermal Drug Delivery System and Method for Using Same | December 2018 | August 2023 | Abandon | 56 | 4 | 1 | Yes | No |
| 16313179 | USE OF AN ESSENTIAL OIL OF EVERLASTING FLOWER IN ORDER TO INCREASE OR RESTORE TACTILE PERCEPTION | December 2018 | April 2021 | Abandon | 27 | 2 | 1 | No | No |
| 16231973 | TREATMENT PROCESS OF CYCLOSPORINE EYE GEL | December 2018 | November 2021 | Allow | 35 | 3 | 0 | No | No |
| 16230399 | BONE REPAIR COMPOSITION AND KIT | December 2018 | November 2020 | Allow | 23 | 1 | 1 | Yes | No |
| 16312079 | CYCLODEXTRIN-GRAFTED CROSS-LINKED HYALURONIC ACID COMPLEXED WITH ACTIVE DRUG SUBSTANCES AND USES THEREOF | December 2018 | December 2020 | Allow | 24 | 1 | 1 | No | No |
| 16224279 | ANHYDROUS, ANTIPERSPIRANT COMPOSITION HAVING IMPROVED STABILITY | December 2018 | April 2021 | Allow | 28 | 3 | 0 | Yes | No |
| 16215081 | ORAL ENERGY PRODUCTS INCLUDING ENCAPSULATED CAFFEINE | December 2018 | January 2021 | Allow | 25 | 2 | 0 | Yes | No |
| 16213655 | ACTIVE INGREDIENT CONTAINING STABILISED SOLID MEDICINAL FORMS AND METHODS FOR THE PRODUCTION THEREOF | December 2018 | January 2020 | Allow | 14 | 1 | 0 | No | No |
| 16304423 | FORMULATIONS OF CHLORAMBUCIL | November 2018 | January 2021 | Abandon | 26 | 2 | 0 | No | No |
| 16098169 | DELAYED-RELEASE TABLETS OF METHYLPHENIDATE | November 2018 | January 2021 | Abandon | 27 | 2 | 0 | No | No |
| 16162839 | ORGANIC HYDROPEROXIDE REDUCTION IN PERFUMERY RAW MATERIALS | October 2018 | August 2019 | Allow | 10 | 1 | 0 | No | No |
| 16160499 | HYDROCOLLOID-BASED SKIN TREATMENT | October 2018 | December 2020 | Allow | 26 | 2 | 1 | Yes | No |
| 16143194 | Curcuminoid Compositions and Preparation Methods | September 2018 | May 2022 | Allow | 44 | 5 | 1 | No | No |
| 16087449 | Treatment of Skin Conditions and Diseases Associated with Microbial Biofilms | September 2018 | April 2020 | Abandon | 19 | 0 | 1 | No | No |
| 16086549 | PROTEIN BASED EXCIPIENT FOR ACTIVE PHARMACEUTICAL INGREDIENTS | September 2018 | January 2022 | Abandon | 40 | 2 | 1 | No | No |
| 16130479 | Seed Adhesive Mixture and Method of Making the Same | September 2018 | April 2020 | Abandon | 19 | 0 | 1 | No | No |
| 16125940 | Personal Cleansing Compositions | September 2018 | October 2021 | Allow | 37 | 4 | 1 | No | No |
| 15761811 | A FAST ACTING ORALLY DISINTEGRATING FILM FOR ADMINISTRATION OF LOCAL ANESTHESIA | September 2018 | October 2022 | Abandon | 55 | 3 | 1 | Yes | No |
| 16077794 | COMPOSITION FOR TOPICAL USE BASED ON A CARNOSINE-MAGNESIUM COMPLEX | August 2018 | December 2020 | Allow | 28 | 2 | 0 | Yes | No |
| 16056759 | PERSONAL CARE DEODORANT PRODUCT VOID OF ENDOCRINE DISRUPTING CHEMICALS | August 2018 | March 2023 | Allow | 56 | 5 | 1 | No | No |
| 16072012 | HYBRID TYPE FOAM AND COSMETIC KIT USING SAME | July 2018 | May 2021 | Abandon | 34 | 2 | 0 | No | No |
| 16025487 | CONTROLLED RELEASE DOSAGE FORMS FOR HIGH DOSE, WATER SOLUBLE AND HYGROSCOPIC DRUG SUBSTANCES | July 2018 | July 2020 | Allow | 24 | 3 | 0 | Yes | Yes |
| 16019623 | SURFACTANT-FREE, WATER-FREE FORMABLE COMPOSITION AND BREAKABLE FOAMS AND THEIR USES | June 2018 | November 2020 | Allow | 29 | 2 | 0 | No | No |
| 16060462 | MAGNESIUM PHOSPHATE HYDROGELS | June 2018 | August 2020 | Allow | 26 | 2 | 0 | Yes | No |
| 15775479 | COMPOSITIONS AND METHODS OF MANUFACTURING PROTEIN MICROPARTICLES | May 2018 | January 2025 | Abandon | 60 | 9 | 1 | Yes | No |
| 15771809 | USE OF BETA-1,3-GLUCAN FOR MODULATING IMMUNE FUNCTION AND TREATING INTESTINAL INFLAMMATION | April 2018 | November 2020 | Allow | 31 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GOTFREDSON, GAREN.
With a 11.1% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 14.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GOTFREDSON, GAREN works in Art Unit 1619 and has examined 480 patent applications in our dataset. With an allowance rate of 39.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner GOTFREDSON, GAREN's allowance rate of 39.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GOTFREDSON, GAREN receive 3.13 office actions before reaching final disposition. This places the examiner in the 86% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by GOTFREDSON, GAREN is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +31.7% benefit to allowance rate for applications examined by GOTFREDSON, GAREN. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 10.3% of applications are subsequently allowed. This success rate is in the 6% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.7% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 70.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 54.2% of appeals filed. This is in the 26% percentile among all examiners. Of these withdrawals, 59.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 65.0% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.